Figure 4.

Antigen uptake and antigen presenting abilities regulated by AYC-EV treatment in DCs exposed to LPS. (a) Immature DCs were stimulated with LPS (100 ng/mL) or with LPS and AYC-EVs (2, 10, and 20 μg/mL). Following incubation for 24 h, cells were exposed to FITC-conjugated Dextran (0.5 mg/mL) for 30 min at 37 °C and 4 °C (negative control for antigen uptake). The cells were then stained using anti-CD11c antibody. CD11c⁺ dextran⁺ cells were detected using flow cytometry. (b) Antigen presenting abilities for MHC-I and MHC-II were confirmed in OVA (MHC-I)- or Eα_44–76 peptide (MHC-II)-treated DCs as described in the material and methods section. OVA_257-264 and Eα_52-68 peptides were used as positive controls for antigen presenting of MHC-I and MHC-II. CD11c⁺25-D1.16⁺ cells indicate OVA_257–264/MHC-I complexes. CD11c⁺Y-Ae⁺ cells indicate Eα_52-68/MHC-II complexes. All bar graphs display mean ± SD (n = 3 samples). All experiments were repeated three times with similar results. ** p < 0.01, *** p < 0.001. Non: untreated DCs, W/O LPS: DCs without LPS treatment, W/ LPS: DCs with LPS treatment, MFI: mean fluorescence intensity.